Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,015 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of two transport systems available in Japan (TERUMO kenkiporter II and BBL Port-A-Cul) for maintenance of aerobic and anaerobic bacteria.
Fujimoto D, Takegawa H, Doi A, Sakizono K, Kotani Y, Miki K, Naito T, Niki M, Miyamoto J, Tamai K, Nagata K, Nakagawa A, Tachikawa R, Otsuka K, Katakami N, Tomii K. Fujimoto D, et al. Among authors: tamai k. J Infect Chemother. 2014 Jan;20(1):26-9. doi: 10.1016/j.jiac.2013.07.008. Epub 2013 Dec 11. J Infect Chemother. 2014. PMID: 24462420
Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.
Fujimoto D, Tomii K, Otoshi T, Kawamura T, Tamai K, Takeshita J, Tanaka K, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Hata A, Tachikawa R, Otsuka K, Hamakawa H, Katakami N, Takahashi Y, Imai Y. Fujimoto D, et al. Among authors: tamai k. Lung Cancer. 2013 May;80(2):159-64. doi: 10.1016/j.lungcan.2013.01.017. Epub 2013 Feb 16. Lung Cancer. 2013. PMID: 23419507
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N. Tanaka K, et al. Among authors: tamai k. J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929. J Thorac Oncol. 2013. PMID: 23591159 Free article.
Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.
Fujimoto D, Ueda H, Shimizu R, Kato R, Otoshi T, Kawamura T, Tamai K, Shibata Y, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K. Fujimoto D, et al. Among authors: tamai k. Clin Exp Metastasis. 2014 Jun;31(5):543-51. doi: 10.1007/s10585-014-9648-3. Epub 2014 Mar 30. Clin Exp Metastasis. 2014. PMID: 24682604
Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients.
Takeshita J, Masago K, Fujita S, Hata A, Kaji R, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Tomii K, Shintani T, Takayama K, Kokubo M, Katakami N. Takeshita J, et al. Among authors: tamai k. Mol Clin Oncol. 2014 May;2(3):454-460. doi: 10.3892/mco.2014.249. Epub 2014 Jan 28. Mol Clin Oncol. 2014. PMID: 24772317 Free PMC article.
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K. Shimizu R, et al. Among authors: tamai k. Cancer Chemother Pharmacol. 2014 Dec;74(6):1159-66. doi: 10.1007/s00280-014-2590-x. Epub 2014 Sep 23. Cancer Chemother Pharmacol. 2014. PMID: 25245821
1,015 results